Clinical observations suggest that antipsychotic effect starts early and increases progressively over time. This time course of antipsychotic effect can be captured in a rat phencyclidine (PCP)-induced hyperlocomotion model, as repeated antipsychotic treatment progressively increases its inhibition of the repeated PCPinduced hyperlocomotion. Although the neural basis of acute antipsychotic action has been studied extensively, the system that mediates the potentiated effect of repeated antipsychotic treatment has not been elucidated. In the present study, we investigated the neuroanatomical basis of the potentiated action of haloperidol (HAL) and clozapine (CLZ) treatment in the repeated PCP-induced hyperlocomotion. Once daily for five consecutive days, adult Sprague-Dawley male rats were first injected with HAL (0.05 mg/kg, sc), CLZ (10.0 mg/kg, sc) or saline, followed by an injection of PCP (3.2 mg/kg, sc) or saline 30 min later, and motor activity was measured for 90 min after the PCP injection. C-Fos immunoreactivity was assessed either after the acute (day 1) or repeated (day 5) drug tests. Behaviorally, repeated HAL or CLZ treatment progressively increased the inhibition of PCP-induced hyperlocomotion throughout the five days of drug testing. Neuroanatomically, both acute and repeated treatment of HAL significantly increased PCP-induced c-Fos expression in the nucleus accumbens shell (NAs) and the ventral tegmental area (VTA), but reduced it in the central amygdaloid nucleus (CeA). Acute and repeated CLZ treatment significantly increased PCPinduced c-Fos expression in the ventral part of lateral septal nucleus (LSv) and VTA, but reduced it in the medial prefrontal cortex (mPFC). More importantly, the effects of HAL and CLZ in these brain areas underwent a time-dependent reduction from day 1 to day 5. These findings suggest that repeated HAL achieves its potentiated inhibition of the PCP-induced hyperlocomotion by acting on the NAs, CeA and VTA, while CLZ does so by acting on the mPFC, LSv and VTA.
Introduction
A growing number of clinical studies suggest that antipsychotic action starts early and increases in magnitude with repeated treatment (Agid et al., 2003 (Agid et al., , 2006 Emsley et al., 2006; Glick et al., 2006; Kapur et al., 2005; Leucht et al., 2005; Raedler et al., 2007) . This observation is strongly supported by the finding that improvement of psychotic symptoms occurs within the first week of treatment and shows a progressive increase over the subsequent weeks. For example, Agid et al. (2003) examined 42 double-blind, comparator-controlled studies (>7000 patients) using a meta-analysis technique. They found that psychotic symptoms improved within the first week of treatment and showed a progressive improvement over subsequent weeks, with the overall pattern of improvement approximating an exponential curve. Leucht et al. (2005) analyzed a large homogeneous database of original patient data from 7 randomized, double-blind studies of the efficacy of amisulpride in patients with schizophrenia spectrum disorders and found the same results. More improvement occurs in the first few days than in any later period of equal duration (Leucht et al., 2005) . Subsequent studies show that the onset occurs within the first day, contemporaneous with the blockade of dopamine receptors (Kapur et al., 2005) , and early nonimprovement (b20% reduction in Brief Psychiatric Rating Scale total score at 1 week) predicts nonresponse at 4 weeks (Correll et al., 2003) .
Animal models play an important role in delineating the time course of antipsychotic action and related behavioral mechanisms (Abekawa et al., 2007; Sun et al., 2009 ). Among many animal models of antipsychotic drugs, the phencyclidine (PCP)-induced hyperlocomotion model seems especially useful for this purpose. First, the PCP model is sensitive to antipsychotic action. Antipsychotic drugs, both typical (haloperidol), 
